文献速递胸部CT

低剂量CT前瞻性观察不同亚型COVID-19患者一年后肺部受累与预后的纵向评估

Longitudinal Assessment of Pulmonary Involvement and Prognosis in Different Subtypes of COVID-19 Patients After One Year Using Low-Dose CT: A Prospective Observational Study.
PubMed 文献 · Acad Radiol · 2025-01-25

前瞻性观察103例住院COVID-19肺炎患者(中、重、危重三组),64例完成出院后3、6、12个月低剂量CT随访。1年时67.19%(43/64)仍有CT异常,9.38%(6/64)见纤维化改变;年龄≥65岁、住院时长及基线实变体积占全肺百分比为1年持续性CT肺部异常的独立危险因素。

要点

  • 出院后1年67.19%(43/64)患者仍有CT异常,其中纤维化改变占9.38%(6/64)。
  • 年龄≥65岁、住院时长、基线实变体积占全肺百分比为1年持续CT异常的独立危险因素。
  • 1年后34.38%(22/64)肺功能仍异常,肺功能与CT表现呈弱相关。

核心结论

  • 感染1年后,即使症状轻微的中度患者中也有超过三分之一存在持续性肺部异常;纤维化改变见于重型和危重型患者,并在出院6个月后保持稳定;影像参数可预测预后,基线实变范围越大,老年患者预后越差。

研究设计与样本

  • 前瞻性观察研究,纳入中国北方103例住院COVID-19肺炎患者,按病情严重程度分为中度、重度、危重三组,64例完成12个月评估;出院后3、6、12个月行低剂量CT,基线与各次随访行定性和定量分析,并记录12个月临床症状与肺功能恢复情况。

诊断标准与关键数值

  • 多因素logistic回归显示年龄≥65岁(OR 8.66;95%CI 1.86, 40.34;P=0.006)、住院时长(OR 1.23;95%CI 1.03, 1.47;P=0.022)、基线实变体积占全肺百分比(OR 56.95;95%CI 1.198, 2706.782;P=0.04)为1年持续性CT肺部异常的独立危险因素。

临床应用与阅片要点

  • 随访中应关注出院后1年仍存在的CT异常及纤维化改变,并重视年龄≥65岁、住院时间长及基线实变范围大的患者。

局限性

  • 103例住院患者中仅64例完成12个月评估。
  • 基线实变体积占全肺百分比作为独立危险因素的OR为56.95,95%CI为1.198至2706.782,置信区间宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Severe COVID-19 typically results in pulmonary sequelae. However, current research lacks clarity on the differences in these sequelae among various clinical subtypes. This study aimed to evaluate the changing lung imaging features and predictive factors in patients with COVID-19 pneumonia in northern China over a 12-month follow-up period after the relaxation of COVID-19 restrictions in 2022.

MATERIALS AND METHODS: Imaging and clinically relevant data from three groups (moderate, severe, and critical) of patients with varying severity were prospectively analyzed. Low-dose CT scans were conducted at 3, 6, and 12 months after discharge, with chest CT images evaluated at baseline and each follow-up using qualitative and quantitative analyses. Clinical symptoms and pulmonary function recovery at 12 months were documented. The correlation between lung function and CT results was analyzed. Univariate and multivariable logistic regression analyses were employed to examine factors influencing prognosis, while a post-hoc analysis model was utilized to investigate the relationships among different groups, time points, and chest CT findings.

RESULTS: Among the 103 hospitalized patients with COVID-19 pneumonia, 64 completed the 12-month evaluation. The median age was 63.70 ± 12.15%, and 62.5% (40/64) were men. During the follow-up period, while 67.19% (43/64) showed abnormalities, including fibrotic changes in 9.38% (6/64). Multivariable logistic regression identified age ≥ 65 (OR: 8.66; 95% CI: 1.86, 40.34; P = 0.006), length of hospital stays (OR: 1.23; 95% CI: 1.03, 1.47; P = 0.022), and baseline consolidation volume as a percentage of the whole lung (OR: 56.95; 95% CI: 1.198, 2706.782; P = 0.04) as independent risk factors for persistent CT lung abnormalities at 1 year. After 1 year, 34.38% (22/64) of patients still had abnormal lung function, and 9.38% (6/64) had pulmonary fibrosis and restrictive ventilatory dysfunction. The relationship between lung function and CT findings is weak correlation. The mixed model analysis revealed significant differences between groups, particularly between the moderate and severe groups, and significant changes in CT values over time.

CONCLUSION: One year after infection, more than one third of even moderate patients with mild symptoms had persistent pulmonary abnormalities. In our study, fibrotic changes were seen in severe and critically ill patients and remained stable 6 months after discharge from hospital. Imaging parameters can predict the prognosis. The larger the extent of baseline consolidation, the worse the prognosis of elderly patients.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Zhao J, Dong L, Jiao X, et al. Longitudinal Assessment of Pulmonary Involvement and Prognosis in Different Subtypes of COVID-19 Patients After One Year Using Low-Dose CT: A Prospective Observational Study. Acad Radiol. 2025. PMID: 39864985. doi:10.1016/j.acra.2025.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。